Sudeb Dalai, MD, PHD
Infectious Disease · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dalai’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A134059 · Current
Licensed to practise in California · since 2015 · expires 2027-01-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$70,342
Medicare paid this office $70,342 for 114 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 56 | $25,977 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $22,261 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,779 | $156 |
| New patient visit (60+ min) | 29 | $5,890 | $203 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 61 | $2,191 | $15 |
Who their Medicare patients are
114 Original Medicare patients in 2024. Average age 78 · Women 39% · Also on Medicaid 12% · Health risk score 2.14. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Chronic kidney disease 42% · Coronary heart disease 38% · Atrial fibrillation 38% · Cancer 31% · Diabetes 29% · Heart failure 25% · Depression 19% · COPD 17% · Dementia 17% · Stroke 13%.
The office billed $256,483, Medicare allowed $90,417 and paid $70,342; for 634 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 114 | 634 | 78 | 2.14 | $256,483 | $70,342 |
| 2023 | 89 | 277 | 76 | 2.04 | $132,804 | $39,778 |
| 2022 | 70 | 209 | 79 | 2.19 | $91,203 | $28,137 |
| 2021 | 77 | 264 | 77 | 2.24 | $112,800 | $33,346 |
| 2020 | 102 | 382 | 77 | 2.30 | $147,416 | $45,456 |
| 2019 | 128 | 365 | 75 | 2.11 | $143,765 | $43,204 |
| 2018 | 50 | 160 | 75 | 1.55 | $59,002 | $18,699 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 42 | $21,120 | $162 |
| New patient visit (60+ min) | 34 | $7,218 | $206 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $5,924 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,399 | $160 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 17 | $724 | $30 |
2022: 5 services
| Long return visit (40+ min) | 33 | $14,112 | $166 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $3,726 | $96 |
| New patient visit (60+ min) | 18 | $3,620 | $201 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,350 | $186 |
| Extended patient service without direct patient contact, first hour | 18 | $1,890 | $105 |
2021: 6 services
| Return visit (30+ min) | 35 | $9,045 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,676 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $4,466 | $97 |
| Long return visit (40+ min) | 17 | $3,587 | $171 |
| Extended patient service without direct patient contact, first hour | 28 | $2,933 | $105 |
| New patient visit (60+ min) | 15 | $2,885 | $192 |
2020: 7 services
| Return visit (30+ min) | 45 | $12,794 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $7,290 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,710 | $186 |
| Long return visit (40+ min) | 23 | $4,589 | $135 |
| New patient visit (60+ min) | 22 | $4,467 | $203 |
| Extended patient service without direct patient contact, first hour | 34 | $4,144 | $106 |
| Extended patient service without direct patient contact, first hour | 22 | $2,323 | $106 |
2019: 6 services
| Return visit (30+ min) | 47 | $9,995 | $98 |
| New patient visit (60+ min) | 49 | $9,129 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $6,557 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 34 | $6,071 | $179 |
| Extended patient service without direct patient contact, first hour | 44 | $4,415 | $100 |
| Long return visit (40+ min) | 25 | $4,371 | $137 |
2018: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $6,085 | $94 |
| New patient visit (60+ min) | 19 | $3,637 | $191 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,729 | $182 |
| Long return visit (40+ min) | 15 | $2,456 | $136 |
| Return visit (30+ min) | 13 | $2,142 | $102 |
Drugs they prescribed that Part D paid
$171,767
Pharmacies billed $171,767 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 274) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
222 generic and 52 brand-name prescriptions · $171,767 in drug cost · 170 antibiotic prescriptions to 43 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Genvoya | 12 | $54,181 | $4,515 |
| Descovy | 22 | $52,342 | $2,379 |
| Ertapenem | 14 | $3,582 | $256 |
| Fosfomycin Tromethamine | 14 | $1,304 | $93 |
| Cefazolin | 24 | $790 | $33 |
See all 12 drugs
| Genvoya | 12 | $54,181 | $4,515 |
| Descovy | 22 | $52,342 | $2,379 |
| Ertapenem | 14 | $3,582 | $256 |
| Fosfomycin Tromethamine | 14 | $1,304 | $93 |
| Cefazolin | 24 | $790 | $33 |
| Nitrofurantoin Mono-Macro | 14 | $711 | $51 |
| Methenamine Hippurate | 17 | $464 | $27 |
| Sulfamethoxazole-Trimethoprim | 15 | $265 | $18 |
| Doxycycline Hyclate | 13 | $225 | $17 |
| Cephalexin | 12 | $209 | $17 |
| Amoxicillin | 21 | $199 | $9 |
| Isoniazid | 11 | $141 | $13 |
Year by year
| 2024 | 274 | 58 | 0% (0) | 19% | $171,767 |
| 2023 | 201 | 45 | 0% (0) | None | $143,390 |
| 2022 | 141 | 38 | 0% (0) | 21% | $91,360 |
| 2021 | 211 | 42 | 0% (0) | 18% | $77,793 |
| 2020 | 224 | 53 | 0% (0) | 19% | $131,318 |
| 2019 | 347 | 53 | 0% (0) | 7% | $31,785 |
| 2018 | 36 | 13 | 0% (0) | None | $6,767 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Genvoya | 12 | $50,148 | $4,179 |
| Descovy | 19 | $44,991 | $2,368 |
| Amoxicillin-Clavulanate Potass | 15 | $981 | $65 |
| Cephalexin | 19 | $663 | $35 |
| Nitrofurantoin Mono-Macro | 11 | $489 | $44 |
| Sulfamethoxazole-Trimethoprim | 12 | $431 | $36 |
| Amoxicillin | 17 | $354 | $21 |
| Nystop | 11 | $239 | $22 |
| Isoniazid | 12 | $151 | $13 |
2022: 4 drugs
| Genvoya | 12 | $45,806 | $3,817 |
| Descovy | 11 | $23,893 | $2,172 |
| Ceftriaxone | 13 | $298 | $23 |
| Sulfamethoxazole-Trimethoprim | 15 | $259 | $17 |
2021: 6 drugs
| Genvoya | 11 | $39,427 | $3,584 |
| Fosfomycin Tromethamine | 16 | $3,814 | $238 |
| Doxycycline Hyclate | 19 | $1,169 | $62 |
| Cephalexin | 19 | $390 | $21 |
| Nystop | 11 | $322 | $29 |
| Amoxicillin | 11 | $66 | $6 |
2020: 5 drugs
| Vancomycin | 32 | $4,458 | $139 |
| Methenamine Hippurate | 27 | $2,477 | $92 |
| Ceftriaxone | 17 | $879 | $52 |
| Nitrofurantoin Mono-Macro | 15 | $411 | $27 |
| Amoxicillin | 13 | $238 | $18 |
2019: 8 drugs
| Vancomycin | 40 | $7,619 | $190 |
| Ertapenem | 18 | $5,035 | $280 |
| Methenamine Hippurate | 30 | $2,776 | $93 |
| Ceftriaxone | 60 | $2,091 | $35 |
| Doxycycline Hyclate | 48 | $1,836 | $38 |
| Amoxicillin-Clavulanate Potass | 46 | $1,148 | $25 |
| Ampicillin | 15 | $930 | $62 |
| Amoxicillin | 13 | $323 | $25 |
Money from drug and device companies
$50 in 2020
A payment is not proof that care is biased.
| Paratek Pharmaceuticals | Nuzyra | $50 | 1 payment
|
See the published payment
| Paratek Pharmaceuticals | Meals · 2020-05-21 | Nuzyra | $50 |
Professional record
- NPI
- 1043656697
- Licence
- CA A134059California A134059: Current · expires 2027-01-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Internal medicine (207R00000X)
- Mailing address
- 795 El Camino Real, Level 2 Lee Bldg, Palo Alto, CA, 94301
- NPI first listed
- 2013-05-21
- NPI last updated
- 2024-04-28
- NPI record certified
- 2024-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Palo Alto, CA, 94304 · 200 W Arbor Dr # 8422, San Diego, CA, 92103